Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects
{{output}}
In the last few years, three new drugs for targeted systemic therapies have been approved for advanced and progressive thyroid cancer, namely vandetanib and cabozantinib for medullary and sorafenib for radioiodine refractory differentiated thyroid cancer. Pati... ...
